The c-jun gene regulates cellular proliferation and apoptosis via direct regulation of cellular gene expression. Alternative splicing of pre-mRNA increases the diversity of protein functions, and alternate splicing events occur in tumors. Here, by targeting the excision of the endogenous c-jun gene within the mouse mammary epithelium, we have identified its selective role as an inhibitor of RNA splicing. Microarray-based assessment of gene expression, on laser capture microdissected c-jun À/À mammary epithelium, showed that endogenous c-jun regulates the expression of approximately 50 genes governing RNA splicing. In addition, genome-wide splicing arrays showed that endogenous c-jun regulated the alternate exon of approximately 147 genes, and 18% of these were either alternatively spliced in human tumors or involved in apoptosis. Endogenous c-jun also was shown to reduce splicing activity, which required the c-jun dimerization domain. Together, our findings suggest that c-jun directly attenuates RNA splicing efficiency, which may be of broad biologic importance as alternative splicing plays an important role in both cancer development and therapy resistance. Cancer Res; 72(4); 1023-34. Ó2011 AACR.
Introduction c-Jun is overexpressed in human tumors that display increased cellular proliferation and DNA synthesis whereas its in vivo disruption prevents hepatocarcinoma (1) . c-Jun overexpression can induce anchorage-independent growth of Rat-1a and human breast MCF-7 cells (2, 3) and can inhibit cellular apoptosis via gene transcription through a p53/ p21 CIP1 -dependent mechanism (1) . c-Jun complexes with Jun/Fos and MaF/Nr1 families members (4) (5) (6) to form an activator protein (AP-1) transcription factor complex that can regulate expression of genes that control G 1 to S-phase progression and diverse cellular functions (7) . c-Jun mediates oncogenic transformation (8) and cellular apoptosis in a cell-and context-dependent manner (9) (10) (11) (12) (13) (14) (15) . c-Jun regulates target gene expression that regulates apoptosis, or regulates cell-cycle progression in the presence of DNA damage and thereby inducing apoptosis (16) . In both scenarios, c-jun functions by regulating the gene transcription via cognate DNA-binding sites in the promoter of apoptosis regulatory genes. c-Jun function in mammary gland development and growth in vivo is largely unknown as the c-jun À/À mice are embryonic lethal (13) . Targeted expression of Cre recombinase in the mammary epithelium of c-jun fl/fl mice (MMTV-Cre/cjun fl/fl ) showed that the loss of c-jun expression in the mammary epithelium correlated with increased apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining (17) although the mechanism by which c-jun inhibits apoptosis remained to be determined. Herein, we interrogated the molecular genetic events regulated by endogenous c-jun in mammary epithelial in vivo. Recent studies have revealed the importance of alternative RNA splicing in cellular apoptosis (18) (19) (20) , in human disease and cancer (21, 22) . Pre-mRNA splicing regulates gene expression in 75% of human genes whereas serine/arginine (SR)-rich proteins mediate both constitutive and alternative splicing (23) and act as a switch that controls the conversion of apoptotic genes into proapoptotic splice variants (24) . Alternative splicing of a subset of genes is enriched in human breast and ovarian cancers. The mechanisms governing alternative splicing in tumors and relative splicing activity are not well understood. The development of a splicing minireporter gene to increase splicing activity has been useful in identifying candidate mechanisms.
Herein, microarray analysis conducted on laser capture microdissected mammary epithelial cells (MEC) from floxed c-jun transgenic mammary epithelium, (devoid of c-jun protein due to Cre-mediated c-jun gene excision), showed that c-jun altered the expression of splicing factors. c-Jun directly attenuated splicing activity and regulated target gene splice variants. A significant proportion of these c-jun-dependent alternatively spliced genes were also alternatively spliced in tumors and in apoptosis. Thus, in addition to mediating apoptosis or cell survival via regulating gene transcription, c-jun regulates the mRNA splicing apparatus and splicing of genes involved in apoptosis.
Materials and Methods
Transgenic mice, mouse embryonic fibroblasts, MECs, expression plasmids, and reagents
Transgenic animals carrying floxed c-jun alleles, c-jun f/f , were previously described (25) . All experimental procedures with these mice were approved by the ethics committee of Thomas Jefferson University (Philadelphia, PA). Primary mouse MEC cultures were prepared by removing the 4th mammary gland from 8-week-old female mice (26) . Production of mouse embryonic fibroblasts (MEF) and 3T3 and their culture conditions were described in other studies (26) (27) (28) . The adenoviruses (Ad-Null and Ad-Cre) used for infecting MEFs or MECs (29) , RSV-c-jun, MSCV-c-jun, and their mutants (30) , the splicing double reporter (31) , and the c-Fos expression vectors, a generous gift of Dr. Tom Curran (32), were previously described.
Immunohistochemistry, mouse mammary gland whole mounts, and Western blots Transgenic animals were euthanized following Institutional Animal Care and Use Committee allowed procedure. Mammary gland whole mounts were prepared as described (33 Reverse  CCG CTA GCA CTC ACG TTG GTA GGC  Reverse  CAG GGC GTT GTG TCA CTG AGC T  Cre  Forward  TGC TCT GTC CGT TTG CCG  Reverse  ATC GTG TCC AGA CCA GGC  c-jun  Forward  AGA CGC GTG CCT ACG GCT ACA GTA A  Reverse  CGA CGT GAG AAG GTC CGA GTT CTT G  RPL-19  Forward  CTG AAG GTC AAA GGG AAT GTG  Reverse  GGA CAG AGT CTT GAT GAT CTC  Splicing reporter  Forward  AAC ATC AGC CGC TAC AGT CAA  Reverse  ACG TGA TGT TCT CCT CGA TAT  Caspase 9 exon 9  Forward  CTA CAC ATG CAG TTG TGG GCG TTT  Reverse  GAT GCA TAA TGG 
Results
Somatic excision of c-jun in the mammary gland reduces MECs in vivo Female progeny, resulting from the crosses between floxed c-jun (c-jun f/f ) or wild-type (c-jun w/w ) mice with MMTV-Cre transgenic mice expressing mammary specific Cre recombinase were used (Fig. 1A-D) . Amplification of a 600-bp PCR fragment in the mammary gland was indicative of successful cjun gene excision by Cre recombinase (Fig. 1B) and consequent reduction in expression of c-jun mRNA transcripts and proteins (<90%; Fig. 1C) . Amplification of residual c-jun mRNA transcripts in whole mammary gland RNA was detected because of the sensitivity of RT-PCR, with resulting amplification from trace amounts of c-jun from other stromal cells, lymphocytes, and macrophages. Immunostaining confirmed the expression of Cre-mRNA transcripts and proteins in the mammary glands (Fig. 1C) . Western blot analysis showed the loss of c-jun protein in whole mammary gland extracts (Fig. 1B) . Laser capture microdissection (LCM) was used to select MECs and extract RNA for all subsequent molecular assays [ Fig. 1D (iii) ]. Both RT-PCR and qRT-PCR on laser capture microdissected RNA confirmed a 10-fold reduction in c-jun expression [ Fig. 1D (iv and v) ].
Endogenous c-jun in MECs inhibits expression of genes governing mRNA splicing
In recent studies of the cellular components of the mammary gland of the bitransgenic mice, we showed an by NIH-DAVID, using Gene Ontology terms to characterize the differentially regulated genes by their molecular function and pathway analysis conducted using ASSESS showed c-junregulated several functional categories (UVA/UVB; RhoGTPases, the G 1 -S reactome, estrogen signaling, E 2 F 1 /E 2 F 1 targets, apoptosis, mRNA processing reactome, and mRNA splicing; ref. 17) . The finding that the loss of endogenous c-jun correlated with the induction of pathways governing mRNA processing and splicing was novel and warranted further investigation. The enrichment for altered expression of individual genes within the mRNA processing reactome ( Fig. 2A ) and the mRNA splicing factors (Fig. 2B ), illustrates that endogenous c-jun regulates the expression of genes involved in mRNA splicing. Splicing factors include both activators and repressors of splicing (34) . The excision of c-jun both induced and repressed activators and repressors of splicing. Members of the SR family (SFR) which encode sequence specific spliceosome factors, basal SnRNA (SNRPB2), and SR repetitive matrix protein 1 (SRRM1) which encode proteins involved in pre-and postsplicing mRNA complexes, were primarily induced but some were repressed in c-jun À/À mammary epithelium. Splicing factors known to function as repressors of splicing (i.e., SNRP70, SNRPN, and SNRPC) were mainly inhibited in c-jun À/À cells. Splicing of pre-mRNA occurs in the spliceosome which consists of 5 ribonucleoprotein subunits. qRT-PCR was, therefore, conducted to determine the mRNA abundance of these components and the mean date of n ¼ 6 for each mRNA is shown as mean dC t values in Fig. 2D . The mean dC t value is essentially the reciprocal of fold change. Expression of key mRNA splicing regulatory genes (sfrs2, hnRNPA, hRNPU, snrpg, srp19, and sf3b3) were increased upon c-jun excision ( 
Endogenous c-jun regulates alternative splicing of genes
These studies indicate that c-jun regulates the abundance of gene products regulating splicing. To determine whether alterations in abundance of genes associated with gene splicing of altered gene splicing in vivo, we examined the alternate splice forms of 28,853 gene transcripts represented on the Mouse Exon 1.0 ST chip. Using the Gene Spring "Core Data Analysis" method and filtering and statistical methods (Fig. 3A) , we determined the gene splicing index (SI). For the determination of the SI, each exonic probe set is normalized by dividing its expression by the gene-level summary value for the entire gene to yield a normalized intensity. The splicing index is then calculated as a fold change between the 2 normalized levels. One hundred fifty six genes were shown to be alternatively spliced in 3 c-jun þ/þ versus 3 cjun À/À mice mammary epithelium (Fig. 3B) . Several of those genes are either known to be involved in apoptosis (caspase-9, caspase-6) or have been linked to disease in which apoptosis is a prominent feature (Kifap3, Park2). The relative abundance of a subset of these genes was validated by qRT-PCR of the affected exons (Fig. 3C) , which is a quantitative indicator of higher abundance of the specific spliced form.
To display a subset of the analysis of the key individual genes and their alternative splicing, the probe sets were indicated on the x-axis and the relative increase or decrease in transcript inclusion or exclusion as a result of cellular mRNA splicing activity is shown as log 10 on the y-axis. The affected gene exons are represented in red below the graphical display of the splicing results ( Supplementary Fig. S1 ).
As a complementary interrogation of the genome subjected to alternative splicing by c-jun, comparison was made of cjun À/À versus c-jun þ/þ MECs, and individual exon mapping was conducted using Plotagene. For ease of display exon map, Plotagene displays the structure of the specified gene, colored according to the expression level of each exon (36) . The average expression of gene is calculated and used to color the overall gene. The genes which are alternatively spliced in a manner dependent upon c-jun and the distribution of the alternately spliced exons, is shown in Fig. 4A . Using this approach, the population of alternatively spliced genes expanded to include 147 genes. The 147 genes and the alteration in expression of the individual exons determined by the relative abundance of c-jun is shown in Fig. 4A . Recent studies have shown that active alternative splicing events are changed in breast/ovarian tumors (37) . A comparison of these alternatively spliced genes with the c-jun-dependent spliced genes showed an overlap of 8 of 147 (Fig. 4B , individual genes shown in Fig. 4A ). An advanced bioinformatics analysis was conducted to map and classify the patterns of the c-jun-dependent alternatively spliced genes into Functional Gene Networks and Disease and Disorder Networks using the Ingenuity Pathways Analyses System (IPA 7.5; Figs. 3 and 4 and Table 2 ). These highest ranked functional networks identified by IPA 7.5 were: Cancer (1) and Cell Death (score: 20; ref. Fig. 4D ). This finding is consistent with the 14 genes correlating with genes involved in apoptosis (Fig. 4A) . Approximately 22% of the alternatively spliced genes within "Disease and Disorder" networks were categorized as cancer related Fig. 4D ). Approximately 54% of the alternatively spliced genes within the top "Molecular and Cellular Function" networks were functionally linked to cell death or cellular compromise (Fig. 4E) . (38) . SC35, SRSF2 (the protein product of the Srsf2 gene), is known to promote the alternative splicing of several genes to enhance their proapoptotic phenotype (38) . Immunohistochemistry for SRSF2 showed increased abundance in a nuclear speckled distribution in c-jun À/À mammary epithelial breast tumor cells (Fig. 5A) and Western blot analysis confirmed increased SRSF2 abundance in c-jun À/À MECs (Fig. 5B) . To determine whether the increased abundance of SRSF2 regulated splicing, siRNA to SrSf2 was deployed in conjunction with a synthetic splicing reporter gene (31; Fig. 5C ). Two distinct siRNAs to Srsf2 enhanced splicing reporter activity by approximately 5-fold (Fig. 5D ). Consistent with the lower level of Srsf2 in c-jun
cells, the induction of splicing activity by Srsf2 siRNA was increased only 2-fold in c-jun À/À cells. The approximately 10-fold increase in SRSF2 was abrogated by reintroduction of Figure 3 . Genome-wide splicing array shows endogenous c-jun governs alternative splicing. Exon inclusion or exclusion (resulting from altered mRNA splicing) was compared in exon arrays using laser capture microdissected RNA from mammary epithelium of Cre a c-jun retroviral expression vector, indicating the effect was specific for c-jun. Thus endogenous c-jun inhibits the expression and abundance of SRSF2 and endogenous SRSF2 is capable of regulating activity of a general splicing activity minigene reporter.
c-Jun repression of a splicing minigene reporter requires the c-jun B-ZIP domain
The mRNA gene expression data are consistent with a role for endogenous c-jun as a regulator of genes regulating RNA splicing. However, whether c-jun directly regulated splicing activity or not remained to be determined. To determine whether c-jun directly repressed splicing, a state-of-the-art splicing reporter gene was deployed (31) . Introduction of the b-galactosidase splicing reporter gene system into c-jun
, when normalized for transfection efficiency, showed an increase in splicing activity in c-jun To identify the domains of c-jun required for repression, a series of c-jun mutant expression vectors were used (Fig. 6D) . c-Jun repression of splicing activity was reduced 60% by deletion of the N-terminal transactivation/transrepression domain. Mutation by point substitution of the leucine zipper abrogated c-jun-mediated repression, whereas the DNA-binding defective mutant maintained repression. Thus, the leucine zipper domain but not the DNA-binding domain is required for c-jun-mediated repression of splicing reporter gene activity. The heterodimeric partner of c-jun for AP-1-mediated repression includes the transcription factor c-Fos. Expression of c-Fos repressed splicing reporter activity (Fig. 6E) . A c-Fos carboxyl terminal deletion failed to abrogate repression. However, a D139 to 145 mutant of c-Fos, failed to repress splicing reporter activity. Collectively, these studies show that endogenous c-jun inhibits splicing activity in both murine MECs and MEFs. The repression by c-jun requires the leucine zipper domain.
Discussion
The current studies provide several independent lines of evidence to support the novel finding that endogenous c-jun regulates gene splicing. First, c-jun regulated a gene expression pathway governing gene splicing. Second, c-jun regulated expression of individual mRNA for the genes that regulate mRNA splicing. Third, genome-wide splicing analyses showed that c-jun excision altered the splicing pattern of 147 genes, 8 of which are alternatively spliced in cancer, and an additional ). The data represent mean AE SEM of n > 5 separate transfections.
Ã , P 0.05; error bar, SEM.
14 of which are involved in cell death. Fourth, c-jun directly regulated the activity of a splicing minigene reporter system requiring the B-ZIP domain. Collectively, these studies show at a genome-wide level, there is a new role for c-jun in regulating gene splicing.
Here, c-jun inhibited the relative abundance of splicing factors including the SRSF2 splicing factor. A subset of alternative splicing events occurs in cancer-related genes and regulates their apoptotic versus proapoptotic splice forms. SRSF2 acts as a switch between the alternate splicing of apoptotic genes (c-flip, caspase-8, caspase-9, and Bcl-X) towards the proapoptotic splice variants (24) . In our studies of c-jun À/À mice, the E 2 F 1 gene signaling pathway was upregulated (17) . In prior studies, the E 2 F 1 upregulated SRSF2 (SC35) in response to DNA damage (24) . Thus, our studies are consistent with a model in which c-jun may inhibit apoptosis via inhibitors of E 2 F 1 and thereby SRSF2 to inhibit alternative splicing of apoptosis genes.
In the current studies, microarray-based genome-wide expression profiling revealed that endogenous c-jun altered splicing of several genes regulating cellular apoptosis. In our recent studies, TUNEL staining confirmed the increased apoptosis in epithelial cells within c-jun À/À mammary glands and a marked reduction in the number of epithelial cells. c-Jun is thought to convey cell type specific pro-or antiapoptotic functions (16) . Thus c-jun conveyed an antiapoptotic function in the mammary epithelium in vivo consistent with prior studies on hepatocytes and fibroblasts using gene knockdown (9, 11, 13, 14, 39) . The exon array identified genes that were alternatively spliced in a c-jun-dependent manner. The biologic pathways in which these alternatively spliced genes participate include cancer and apoptosis.
Several alternatively spliced genes which were regulated by c-jun include antiapoptotic growth factors and cytokines, such as sclerostin domain containing 1 (sostdC1) which associates with bone morphogenetic proteins (BMP) blocking their binding to their receptors thereby regulating BMP function in cell death. Latent TGF-b binding protein (ltbP4) and oncostatin M receptor (Osmr) are proapoptotic proteins that were alternatively spliced in a c-jun-dependent manner, other proteins include caspase-9, caspase-6, Tnfrsf12A, and Park2 (Parkinson's disease autosomal recessive juvenile 2) which protects neurons against apoptosis. Alternative splicing of caspase-9 has been linked to its apoptotic function (40, 41) . SRSF2, for example enhances the proapoptotic forms of caspase-9 and herein c-jun attenuated the expression of SRSF2 (24) . The current studies showed an enrichment of genes alternatively spliced in tumors amongst the c-jun-mediated alternatively spliced genes. Alternative splicing may contribute to human disease and cancer via different mechanisms (21, 22) .
A number of important targets participating in the onset and progression of tumorigenesis are regulated via alternative splicing. However, the molecular mechanisms regulating expression of splicing factors during tumorigenesis are not fully understood (42) . Splicing factors and gene splicing are differentially regulated in various tumors (43) . c-Jun is overexpressed in a human tumors where it promotes cellular proliferation via transcriptional induction of cyclin D1 (7). The current studies raise the possibility that the induction of c-jun expression in tumors may contribute to the altered splicing that occurs during tumorigenesis. The previous models suggest that c-jun regulates cell survival in one or the 2 ways as follows: (i) it alters the transcription of proand antiapoptotic gene products (FasL, Bim, and Bcl3; ref. 44) , and the relative balance in gene expression determines the apoptotic or survival phenotype; or (ii) c-jun regulates apoptosis via its indirect effects (45) , wherein, cjun functions as a homeostatic regulator of cell proliferation. Aberrant control of the cell cycle by c-jun contributes to apoptosis. The current studies show that endogenous c-jun inhibits MEC apoptosis and alters splicing of genes involved in apoptosis, raising the possibility that c-jun may mediate apoptosis by regulating the splicing efficiency of pro-versus antiapoptotic genes.
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